Swiss Market Ends Weak After Cautious Session

The Swiss market closed slightly weaker after a cautious session, with the SMI falling 26.34 points (-0.24%) to 11,128.24 after oscillating in a tight intraday range. Defensive and large-cap names led declines — Alcon, Lonza, Sika, Novartis and Swisscom all fell around 1–2.6% — while Roche outperformed, rising 1.56% after U.S. FDA approval for its Xofluza influenza drug. Big financials also showed pockets of strength: Credit Suisse climbed ~1.8% and UBS advanced 1.2%. Several mid-cap names slipped 2–3.5%, weighing on the broader mid-price index. Overall the tone was cautious-to-weak, with mixed sector performances limiting broader upside.